{ "schemaVersion": 1, "organisationId": "O-8cf89756f716407aa3da8a23487fcc4a", "slug": "roivant-sciences-ltd", "name": "Roivant Sciences Ltd.", "updatedAt": "2026-10-02T11:21:11.768615Z", "sections": [ { "type": "OVERVIEW", "text": "Roivant Sciences Ltd. is a biopharmaceutical company that develops and commercializes medicines through focused subsidiary companies called “Vants.” It also incubates discovery-stage companies and health-technology startups that complement its biopharmaceutical business. Roivant describes its mission as improving patients’ lives by accelerating the development and commercialization of medicines that matter. [P119912468] The company was founded in 2014. [https://www.roivant.com/about/company]\n\nIts business is defined by developing a portfolio of medicines, including candidates for autoimmune and pulmonary diseases. Roivant’s listed office locations are New York City and Basel, Switzerland. [https://www.roivant.com/contact] For the fiscal year ended March 31, 2026, it reported revenue of $8.3 million, primarily from Genevant license agreements. [P75136564]\n[P119912468][https://www.roivant.com/about/company][https://www.roivant.com/contact][P75136564][https://www.roivant.com/about/company][https://www.roivant.com/contact]", "updatedAt": "2026-10-02T11:21:11.768615Z" }, { "type": "PRODUCTS", "text": "Roivant’s marketed product is LISRAYA™ (brepocitinib), an oral, once-daily JAK1/TYK2 inhibitor approved in the U.S. for adults with dermatomyositis [https://investor.roivant.com/news-releases/news-release-details/roivant-announces-fda-approval-lisrayatm-brepocitinib-adults]. Brepocitinib is also being developed for non-infectious uveitis, cutaneous sarcoidosis, and lichen planopilaris; a Phase 3 non-infectious uveitis study has been initiated [https://www.roivant.com/pipeline][https://investor.roivant.com/news-releases/news-release-details/priovant-announces-first-patients-enrolled-phase-3-study-beacon].\n\nOther named clinical-stage products include IMVT-1402, a fully human anti-FcRn monoclonal antibody being studied for autoimmune diseases including rheumatoid arthritis, Graves’ disease, myasthenia gravis, CIDP, and Sjögren’s disease [https://www.roivant.com/pipeline]. In an early study, weekly 600 mg dosing reduced mean total IgG by 74% after four doses; development for cutaneous lupus erythematosus was later discontinued after the proof-of-concept study missed its primary endpoint [P93845906][P117179771][https://investor.roivant.com/news-releases/news-release-details/roivant-announces-topline-results-proof-concept-study-imvt-1402/]. Mosliciguat is an inhaled soluble guanylate cyclase activator in development for pulmonary hypertension associated with interstitial lung disease; its Phase 2 study reported a 56.3% reduction in pulmonary vascular resistance versus placebo at Week 16, and Phase 3 development was underway [P87408662][https://investor.roivant.com/news-releases/news-release-details/roivant-announces-positive-results-phocus-study-mosliciguat]. Company disclosures describe drug discovery capabilities including quantitative proteomics, induced proximity, and covalency; they do not identify a separate external service offering [P120865333].\n[P93845906][P117179771][P87408662][P120865333][https://investor.roivant.com/news-releases/news-release-details/roivant-announces-fda-approval-lisrayatm-brepocitinib-adults][https://www.roivant.com/pipeline][https://investor.roivant.com/news-releases/news-release-details/priovant-announces-first-patients-enrolled-phase-3-study-beacon][https://investor.roivant.com/news-releases/news-release-details/roivant-announces-topline-results-proof-concept-study-imvt-1402/][https://investor.roivant.com/news-releases/news-release-details/roivant-announces-positive-results-phocus-study-mosliciguat]", "updatedAt": "2026-10-02T11:21:11.768615Z" }, { "type": "GEOGRAPHY", "text": "Roivant lists its principal executive-office address in London, UK, and maintains offices in New York and Basel, Switzerland [P69922249][T7785279][https://www.roivant.com/contact]. Its subsidiary Roivant Sciences, Inc. leases 54,702 square feet at One Penn Plaza in New York for the U.S. corporate headquarters; Roivant reports that it owns no properties [P36265381][P67689052].\n\nThe company states that its employees and operations are primarily located in the United States [P58904244]. Its clinical development includes a global, multicenter Phase 2 trial [P123275700]. Roivant does not disclose revenue by country or region, or an employee headcount by geography, in the cited FY2026 materials [P28973557].\n[P69922249][T7785279][P36265381][P67689052][P58904244][P123275700][P28973557][https://www.roivant.com/contact]", "updatedAt": "2026-10-02T11:21:11.768615Z" }, { "type": "SEGMENTS", "text": "Roivant Sciences Ltd. reports one operating and reportable segment: the discovery, development and commercialization of medicines and technologies. Its CEO is the chief operating decision maker; the company does not report separate GAAP segments by Vant, therapeutic area, or product. [P4555074][P28973557]\n\nFor the year ended March 31, 2026, the sole reportable segment accounted for all reported consolidated revenue: $8.260 million, or 100% of segment revenue. Roivant describes its Vants as independently managed biotech companies with their own missions and product candidates, but does not disclose their individual revenue contributions as reportable segments. [T10005737][P44648594][P4555074]\n[P4555074][P28973557][T10005737][P44648594]", "updatedAt": "2026-10-02T11:21:11.768615Z" }, { "type": "HISTORY", "text": "Roivant Sciences was founded on April 7, 2014, by Vivek Ramaswamy. Initially registered as Valor Biotechnology Ltd., it adopted the Roivant name in November 2014 and developed a model of building focused subsidiary biotechnology companies, or “Vants.” [P53224882][P2027040][https://investor.roivant.com/news-releases/news-release-details/roivant-sciences-announces-change-its-board-directors] In 2015, its subsidiary Axovant completed an initial public offering, an early example of the Vant model. [https://www.sec.gov/Archives/edgar/data/1636050/000104746915005125/a2224888zs-1a.htm][https://www.prnewswire.com/news-releases/axovant-sciences-ltd-announces-completion-of-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares-300100054.html]\n\nIn December 2019, Roivant transferred interests in five Vants—Myovant, Urovant, Enzyvant, Altavant and Spirovant—to Sumitomo Pharma. [P46673057] A Myovant-developed medicine, relugolix (Orgovyx), was approved by the FDA for advanced prostate cancer in December 2020. [https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-relugolix-advanced-prostate-cancer] In January 2021, Ramaswamy stepped down as CEO and Matthew Gline took the role; Roivant completed its business combination with Montes Archimedes Acquisition Corp. in September 2021 and began trading on Nasdaq as ROIV. [P163970924][https://investor.roivant.com/news-releases/news-release-details/roivant-sciences-announces-change-its-board-directors][https://investor.roivant.com/news-releases/news-release-details/roivant-sciences-reports-first-fiscal-quarter-2021-financial] Roivant and Pfizer formed Telavant in 2022 to develop RVT-3101; Roche acquired Telavant in December 2023. [P5407731][P7547005] In October 2024, Organon completed its acquisition of Dermavant. [P109275729]\n[P53224882][P2027040][P46673057][P163970924][P5407731][P7547005][P109275729][https://investor.roivant.com/news-releases/news-release-details/roivant-sciences-announces-change-its-board-directors][https://www.sec.gov/Archives/edgar/data/1636050/000104746915005125/a2224888zs-1a.htm][https://www.prnewswire.com/news-releases/axovant-sciences-ltd-announces-completion-of-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares-300100054.html][https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-relugolix-advanced-prostate-cancer][https://investor.roivant.com/news-releases/news-release-details/roivant-sciences-reports-first-fiscal-quarter-2021-financial]", "updatedAt": "2026-10-02T11:21:11.768615Z" } ], "sources": [ { "id": "P119912468", "href": "https://app.finbar.com/go?id=P119912468", "label": "Roivant Sciences Ltd. — Full financial report (2026 Y)", "documentId": "D-a7e3674013bc422c95cf54bbdf07f798" }, { "id": "https://www.roivant.com/about/company", "href": "https://www.roivant.com/about/company", "label": "www.roivant.com" }, { "id": "https://www.roivant.com/contact", "href": "https://www.roivant.com/contact", "label": "www.roivant.com" }, { "id": "P75136564", "href": "https://app.finbar.com/go?id=P75136564", "label": "Roivant Sciences Ltd. — Full financial report (2026 Y)", "documentId": "D-a7e3674013bc422c95cf54bbdf07f798" }, { "id": "https://investor.roivant.com/news-releases/news-release-details/roivant-announces-fda-approval-lisrayatm-brepocitinib-adults", "href": "https://investor.roivant.com/news-releases/news-release-details/roivant-announces-fda-approval-lisrayatm-brepocitinib-adults", "label": "investor.roivant.com" }, { "id": "https://www.roivant.com/pipeline", "href": "https://www.roivant.com/pipeline", "label": "www.roivant.com" }, { "id": "https://investor.roivant.com/news-releases/news-release-details/priovant-announces-first-patients-enrolled-phase-3-study-beacon", "href": "https://investor.roivant.com/news-releases/news-release-details/priovant-announces-first-patients-enrolled-phase-3-study-beacon", "label": "investor.roivant.com" }, { "id": "P93845906", "href": "https://app.finbar.com/go?id=P93845906", "label": "Roivant Sciences Ltd. — Full financial report (2026 Y)", "documentId": "D-a7e3674013bc422c95cf54bbdf07f798" }, { "id": "P117179771", "href": "https://app.finbar.com/go?id=P117179771", "label": "Roivant Sciences Ltd. — Full financial report (2026 Y)", "documentId": "D-a7e3674013bc422c95cf54bbdf07f798" }, { "id": "https://investor.roivant.com/news-releases/news-release-details/roivant-announces-topline-results-proof-concept-study-imvt-1402/", "href": "https://investor.roivant.com/news-releases/news-release-details/roivant-announces-topline-results-proof-concept-study-imvt-1402/", "label": "investor.roivant.com" }, { "id": "P87408662", "href": "https://app.finbar.com/go?id=P87408662", "label": "Roivant Sciences Ltd. — Full financial report (2026 Y)", "documentId": "D-a7e3674013bc422c95cf54bbdf07f798" }, { "id": "https://investor.roivant.com/news-releases/news-release-details/roivant-announces-positive-results-phocus-study-mosliciguat", "href": "https://investor.roivant.com/news-releases/news-release-details/roivant-announces-positive-results-phocus-study-mosliciguat", "label": "investor.roivant.com" }, { "id": "P120865333", "href": "https://app.finbar.com/go?id=P120865333", "label": "Roivant Sciences Ltd. — Full financial report (2026 Y)", "documentId": "D-a7e3674013bc422c95cf54bbdf07f798" }, { "id": "P69922249", "href": "https://app.finbar.com/go?id=P69922249", "label": "Roivant Sciences Ltd. — Full financial report (2026 Y)", "documentId": "D-a7e3674013bc422c95cf54bbdf07f798" }, { "id": "T7785279", "href": "https://app.finbar.com/go?id=T7785279", "label": "Roivant Sciences Ltd. — Full financial report (2026 Y)", "documentId": "D-a7e3674013bc422c95cf54bbdf07f798" }, { "id": "P36265381", "href": "https://app.finbar.com/go?id=P36265381", "label": "Roivant Sciences Ltd. — Full financial report (2026 Y)", "documentId": "D-a7e3674013bc422c95cf54bbdf07f798" }, { "id": "P67689052", "href": "https://app.finbar.com/go?id=P67689052", "label": "Roivant Sciences Ltd. — Full financial report (2026 Y)", "documentId": "D-a7e3674013bc422c95cf54bbdf07f798" }, { "id": "P58904244", "href": "https://app.finbar.com/go?id=P58904244", "label": "Roivant Sciences Ltd. — Full financial report (2026 Y)", "documentId": "D-a7e3674013bc422c95cf54bbdf07f798" }, { "id": "P123275700", "href": "https://app.finbar.com/go?id=P123275700", "label": "Roivant Sciences Ltd. — Presentation (2026 Y), p26", "documentId": "D-a1b13edf3a654f8497de2ad5c19c949c", "page": 26 }, { "id": "P28973557", "href": "https://app.finbar.com/go?id=P28973557", "label": "Roivant Sciences Ltd. — Full financial report (2026 Y)", "documentId": "D-a7e3674013bc422c95cf54bbdf07f798" }, { "id": "P4555074", "href": "https://app.finbar.com/go?id=P4555074", "label": "Roivant Sciences Ltd. — Full financial report (2026 Y)", "documentId": "D-a7e3674013bc422c95cf54bbdf07f798" }, { "id": "T10005737", "href": "https://app.finbar.com/go?id=T10005737", "label": "Roivant Sciences Ltd. — Full financial report (2026 Y)", "documentId": "D-a7e3674013bc422c95cf54bbdf07f798" }, { "id": "P44648594", "href": "https://app.finbar.com/go?id=P44648594", "label": "Roivant Sciences Ltd. — Full financial report (2026 Y)", "documentId": "D-a7e3674013bc422c95cf54bbdf07f798" }, { "id": "P53224882", "href": "https://app.finbar.com/go?id=P53224882", "label": "Roivant Sciences Ltd. — Full financial report (2025 Y)", "documentId": "D-e3effa039caa4a23977a5d7990fdf384" }, { "id": "P2027040", "href": "https://app.finbar.com/go?id=P2027040", "label": "Roivant Sciences Ltd. — Full financial report (2025 Y)", "documentId": "D-e3effa039caa4a23977a5d7990fdf384" }, { "id": "https://investor.roivant.com/news-releases/news-release-details/roivant-sciences-announces-change-its-board-directors", "href": "https://investor.roivant.com/news-releases/news-release-details/roivant-sciences-announces-change-its-board-directors", "label": "investor.roivant.com" }, { "id": "https://www.sec.gov/Archives/edgar/data/1636050/000104746915005125/a2224888zs-1a.htm", "href": "https://www.sec.gov/Archives/edgar/data/1636050/000104746915005125/a2224888zs-1a.htm", "label": "www.sec.gov" }, { "id": "https://www.prnewswire.com/news-releases/axovant-sciences-ltd-announces-completion-of-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares-300100054.html", "href": "https://www.prnewswire.com/news-releases/axovant-sciences-ltd-announces-completion-of-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares-300100054.html", "label": "www.prnewswire.com" }, { "id": "P46673057", "href": "https://app.finbar.com/go?id=P46673057", "label": "Roivant Sciences Ltd. — Full financial report (2025 Y)", "documentId": "D-e3effa039caa4a23977a5d7990fdf384" }, { "id": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-relugolix-advanced-prostate-cancer", "href": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-relugolix-advanced-prostate-cancer", "label": "www.fda.gov" }, { "id": "P163970924", "href": "https://app.finbar.com/go?id=P163970924", "label": "Roivant Sciences Ltd. — Ipo (2021 O)", "documentId": "D-e4377b7298794dd5a80ea3e7d0c84511" }, { "id": "https://investor.roivant.com/news-releases/news-release-details/roivant-sciences-reports-first-fiscal-quarter-2021-financial", "href": "https://investor.roivant.com/news-releases/news-release-details/roivant-sciences-reports-first-fiscal-quarter-2021-financial", "label": "investor.roivant.com" }, { "id": "P5407731", "href": "https://app.finbar.com/go?id=P5407731", "label": "Roivant Sciences Ltd. — Full financial report (2026 Y)", "documentId": "D-a7e3674013bc422c95cf54bbdf07f798" }, { "id": "P7547005", "href": "https://app.finbar.com/go?id=P7547005", "label": "Roivant Sciences Ltd. — Full financial report (2026 Y)", "documentId": "D-a7e3674013bc422c95cf54bbdf07f798" }, { "id": "P109275729", "href": "https://app.finbar.com/go?id=P109275729", "label": "Roivant Sciences Ltd. — Full financial report (2026 Y)", "documentId": "D-a7e3674013bc422c95cf54bbdf07f798" } ] }